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The Food and Drug Administration (FDA) has sought an injunction to prevent a US-based company from
offering an autologous adult stem cell treatment for musculoskeletal and spinal injuries. Given the alarming
number of clinics promoting stem-cell-based interventions, the outcome of this case could have wide-
ranging implications.In recent years, there has been a massive
increase in clinics claiming to offer treat-
ments or interventions with human adult
stem cells (ASCs). These interventions
generally are offered by privately owned
clinics via the Internet and are often tar-
geted at an improbable range of condi-
tions, including Alzheimer’s disease,
autism, cardiovascular diseases, cerebral
palsy, Down’s syndrome, diabetes, HIV/
AIDS, erectile dysfunction, infertility,
epilepsy, multiple sclerosis, arthritis, Par-
kinson’s disease, and spinal cord injuries
(Kiatpongsan and Sipp, 2009; Regenberg
et al., 2009). While it is hoped that ASCs
may one day be useful in some of these
conditions, many of these uses lack clear
scientific rationale, and none of them has
been demonstrated to be safe or effective
(Lau et al., 2008). Despite the experi-
mental status of these interventions, they
are generally offered for hefty fees and
without regulatory approval. Many of the
clinics operate in locales that have weak
regulatory infrastructures to monitor and
assess the claims made, such as the
Bahamas, China, and Mexico. However,
an increasing number operate in the US
and European Union.
One such clinic is a Colorado-based
company in the US, Regenerative Sci-
ences, Inc. Through its website, this com-
pany is marketing a procedure for mus-
culoskeletal and spinal injuries using
autologous mesenchymal stem cells
(MSCs). In July of 2008, the FDA issued
notice to the company’s medical director
that the procedure was in violation of
federal regulations. If the FDA is success-
ful in seeking this injunction, Regenerative
Sciences will have to cease using these
cells in patients and the status quo willpresumably remain in place. However, if
the FDA loses the case, that decision
could pave the way for virtually anyone
with a medical license to culture autolo-
gous ASCs and inject them back into
patients, without any regulatory oversight.FDA Regulation of Human Cells
and Tissue-Based Products
The FDA regulates interstate commerce in
human cells and tissue-based products
(HCT/Ps) under the Public Health Service
(PHS) Act and the Code of Federal Regu-
lations for Food and Drugs (CFR). HCT/Ps
are defined under the CFR as ‘‘articles
containing or consisting of human cells
or tissues that are intended for implanta-
tion, transplantation, infusion, or transfer
into a human recipient’’ (21 CFR x
1271.3(d)). Cell-based products that
meet this definition require premarket
approval before they can be sold com-
mercially unless they are exempt as a
‘‘361 product.’’ Exemptions for 361 prod-
ucts are permitted if the HCT/P meets all
of the conditions stated in Section
1271.10 of the CFR. These rules state
that HCT/Ps must be:
(1) Minimally manipulated, and
(2) Intended only for homologous use,
and
(3) Not combined with another article
(except for water, or sterilizing, pre-
servation, or storage agents), and
(4) Either:a. Have no systemic or metabolic
effect, or
b. Be forautologoususe, allogeneic
use in first- or second-degree
blood relative, or reproductive
use.Cell Stem Cell 9,HCT/Ps that meet all of these criteria
are regulated as biologics solely under
Section 361 of the PHS Act, while those
that do not are also classified as drugs
and so are regulated under Section 351
as well as the CFR. Classification as a
351 HCT/P means that if the biologic
does not already have market approval,
it may be administered only under an
Investigational New Drug (IND) applica-
tion. IND applications must be accompa-
nied with preclinical data, including
animal pharmacology and toxicology
studies, and detailed protocols for pro-
posed clinical studies that have been
approved by an Institutional Review
Board (IRB). Exemptions to this rule are
permitted under the FDA’s program for
expanded access to INDs for ‘‘com-
passionate uses’’ in small patient popula-
tions (between 10 and 100), although
physicians are still required to submit
an application detailing the rationale for
the intended use, toxicology information,
and IRB approval (Hyun, 2010). Other-
wise, manufacturers of 351 HCT/Ps
must be registered with the Centre for
Biologics Evaluation and Research
(CBER) and hold a valid biologics license,
which would only be issued after the
safety and efficacy of a product is demon-
strated, typically through formal clinical
trials.
Similar laws and authorities exist in
the European Union and in other countries
such as Canada and Australia (Sipp,
2010). These authorities regulate inter-
state commerce in drugs, devices, and
biologics, but not medical practice or
procedures. The use of biological prod-
ucts that fall outside the purview of fed-
eral regulators is considered a medicalNovember 4, 2011 ª2011 Elsevier Inc. 393
Figure 1. Timeline Summarizing Events of Legal Proceedings
between the FDA and Regenerative Sciences in the US District
Courts (USDC) of Colorado and Columbia from 2008–2011
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include skin engraftments,
peripheral or umbilical cord
blood (UCB) stem cell trans-
plants (for autologous use or
use in a first- or second-
degree blood relative), and
reproductive cells and tissues
for in vitro fertilization (IVF).
These procedures are instead
regulated by professional
practice standards, state
licensing boards, profes-
sional accreditation bodies,
third party payers, and
medical malpractice laws
(Taylor, 2010). The lawsuit
involving Regenerative Sci-
ences is testing whether theFDA has the authority to determine if
the expansion of autologous ASCs in
culture is a medical procedure or drug
manufacturing.
Regenerative Sciences versus
the FDA
The legal dispute (see Figure 1 for a time-
line summarizing events) began with an
untitled letter sent by the FDA (2008) to
Regenerative Sciences stating that the
MSCs being marketed on their website
were HCT/Ps and thus required a valid
biologics license. In this letter, the FDA
claimed that the MSCs were not exempt
as a 361 HCT/P because they were in-
tended for nonhomologous use. That is,
cells were being drawn from the patients’
bone marrow and sent to a lab to be iso-
lated and cultured before being inserted
into the injured areas of the patient’s
knees, hands, ankles, etc. As no valid
biologics license was (or is) in effect for
these cells, the FDA requested that the
company cease being in violation of the
PHS Act. To comply, the company would
need to either apply for an IND and/or bio-
logics license, or cease selling the pro-
duct. Regenerative Sciences responded
by denying that the MSCs used in their
procedure were drugs or biological prod-
ucts and, therefore, that they should not
fall under the regulatory authority of the
FDA.
According to court documents, Regen-
erative Sciences first filed a complaint in
the US District Court of Colorado on
February 26, 2009 for a protective order
against the FDA to prevent it from carrying
out inspections of the company’s facili-394 Cell Stem Cell 9, November 4, 2011 ª20ties. This motion was denied. However,
the company also filed a complaint
alleging that the regulatory definition of
HCT/Ps was too broad and it was not an
intention of Congress to give the FDA
authority to regulate autologous uses of
HCT/Ps or ‘‘the practice of medicine.’’
This complaint was dismissed in March
2010 but was followed by another
lawsuit in June to prevent the FDA from
issuing a cease-and-desist order. In this
second complaint, which was filed in
the US District Court of Columbia, it
is claimed that the activities of Regenera-
tive Sciences constitute medical prac-
tice. It is also claimed that the FDA’s
actions would bankrupt the company by
causing patients to avoid treatment at
the clinic and demand refunds on unused
cells that remain in cryostorage. Accord-
ing to the motion filed, Regenerative
Sciences had 242 samples stored at
a cost of $5,000–$8,000 each, as well as
$236,500 worth of procedures owing,
implying a potential liability of over $1
million.
In August 2010, the FDA responded
with an injunction of its own to perma-
nently prevent Regenerative Sciences
from using the MSCs in patients. In this
lawsuit, which has been filed by the
Department of Justice on behalf of the
FDA, it is claimed that the cells are an
adulterated biological drug product that
should be licensed, branded, and manu-
factured according to current good
manufacturing practices as an Rx drug.
However, rather than focusing on the
nonhomologous uses of these cells, the
FDA is now arguing that the product is11 Elsevier Inc.not exempt from premarket
approval because the use
of other articles in the
manufacturing process, such
as growth factors from the
patient’s blood, enzymes,
reagents, and other drug pro-
ducts that are shipped in
interstate commerce, does
not constitute minimal ma-
nipulation. The FDA has since
filed motions for a summary
judgment and dismissal of
the company’s counter-
claims. Regenerative Sci-
ences has ceased performing
the procedure while a deci-
sion is pending, although it
remains on their website.When contacted, the FDA was unable
to comment on why they had shifted
focus away from the intended use of the
MSCs to their manipulation in culture.
One could speculate that, in this case,
stem cells of connective tissues being
used to repair connective tissues might
constitute homologous use, even if those
cells are retrieved from another source
(i.e., the bone marrow). The FDA con-
siders HCT/Ps to be homologous when
they are used to perform the ‘‘same basic
function’’ as the cells or tissues being re-
paired or replaced (21 CFR x 1271.3(c)).
Thus, the retrieval of stem cells from
UCB for the hematopoietic reconstitution
of bone marrow function is considered
homologous use, even though the cells
are sourced from an anatomically dif-
ferent part of the body.
One could also speculate that the FDA
shifted focus once it was able to conduct
inspections and make determinations on
how the cells were being cultured. The
definition of ‘‘minimal manipulation’’ is
codified in Federal Registration rules as
‘‘processing that does not alter the rele-
vant biological characteristics of cells or
tissues’’ (66 Fed. Reg. 5467). Specific
examples of minimal manipulation pro-
vided in the preamble include density
gradient separation; selective removal of
B cells, malignant cells, red blood cells,
or platelets; and centrifugation. It is then
stated explicitly that ‘‘we do not agree
that the expansion of mesenchymal cells
in culture or the use of growth factors to
expand umbilical cord blood stem cells
are minimal manipulation’’ (66 Fed. Reg.
5457). Regenerative Sciences is disputing
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countering that the FDA has not properly
followed the American Procedures Act
by failing to explain how cell expansion
alters the relevant biological characteris-
tics of the cells and issuing a rule without
using legislative rulemaking procedures.
Thorough analyses of the legal issues
raised in this lawsuit are well beyond the
scope of this article, particularly as it
continues to develop. In late August, the
judge issued an order to show cause,
which questions the FDA’s definition of
the term ‘‘drug’’ as being too broad. While
it is too early to determine the implications
of this request, some are speculating that
it could severely undermine the authority
of CBER to regulate biologics as drugs.
The case continues.
The Emerging Politics
of Autologous ASCs
Regardless of how this case is resolved, it
is reasonable to expect that the decision
will be appealed. However, even if Regen-
erative Sciences does not appeal, the
current political environment in the US is
ripening for further challenges against
the FDA’s jurisdiction. In August of this
year, it was reported that the Governor
of Texas and 2012 presidential candidate
for the Republican Party, Rick Perry, had
undergone a procedure involving his
own stem cells. While details have yet
to emerge, the procedure reportedly in-
volved adipose-derived stem cells that
were removed from Perry by liposuction,
grown in culture, and injected into his
spine and bloodstream for a ‘‘reoccurring
back ailment’’ (Marchione, 2011). The
procedure apparently was carried out in
an undisclosed location by a Houston
orthopedic surgeon who had never per-
formed the procedure before.
Speculation has emerged over the
legality of the procedure, which on the
face of it, would appear to be in violation
of the CFR. However, prior to the proce-
dure, Perry was reportedly involved in
the passage of a health care bill that
authorized creation of a state ASC bank
and had been in discussions with the
Texas Medical Board about regulating
ASC procedures. The Board has since
announced that it would be taking steps
to provide oversight of stem cell trans-
plants as a medical procedure. According
to this rule, Texas physicians would have
to gain approval from an accredited IRBand follow state and federal laws concern-
ing the use of therapeutic agents. While
the rule has not yet been written, it would
seem logical to assume that those laws
refer to the FDA regulations on HCT/Ps.
Reports of elite American athletes
receiving autologous ASC interventions
for sports injuries are also emerging.
Quarterback Peyton Manning reportedly
flew to an unspecified location in Europe
to have adipose-derived stem cells in-
jected into his neck, and major league
baseball player Bartolo Colon went to
the Dominican Republic for a procedure
using cells cultured from his bone marrow
and fat tissue. Because these procedures
were administered overseas, the doctors
involved do not appear to have broken
any US laws. However, the concern with
these high profile incidences is the legiti-
mating effects they may have on shaping
public perceptions of autologous ASCs
and encouraging others to undergo risky
procedures that have not yet been shown
to be safe or effective. Thus, even if the
FDA wins its case against Regenerative
Sciences, the underlying regulatory and
political issues surrounding autologous
ASCs may not easily disappear.
The Need for New Regulatory
Approaches
The underlying regulatory and political
issues surrounding autologous ASCs are
likely to persist in part because the current
regulatory frameworks do not sufficiently
capture the complexities of new and inno-
vative stem-cell-based therapies (Hyun,
2010; Taylor, 2010). To provide better
oversight, the International Society for
Stem Cell Research has published Guide-
lines for the Clinical Translation of Stem
Cells (Hyun et al., 2008). These guidelines
encourage scientists and clinicians to
investigate novel stem cell interventions
within clinical trials while allowing limited
scope for physicians to be innovative
with stem cells outside of this context.
However, the conditions outlined in the
guidelines for ‘‘innovative treatments’’
would not satisfy current FDA require-
ments (Cohen and Cohen, 2010). The
guidelines also are not legally binding.
If novel interventions with ASCs are to
be considered as medical procedures,
then it would be important for the medical
profession to take leadership in providing
physicians with adequate guidance and
enforcing sanctions where appropriate.Cell Stem Cell 9,In 2010, the British General Medical
Council struck a doctor off the medical
register for exploiting vulnerable patients
and unjustifiably administering inappro-
priate ASC treatments. The move on
behalf of the Texas Medical Board to
issue new rules on using stem cells is
also promising, although it is unclear if
this is indicative of an emerging national
trend. Even if state medical boards were
to develop their own guidelines, the re-
sulting national framework would remain
patchy at best as the rules could vary
considerably from state to state.
Given these limitations, and the preva-
lence of privately owned clinics that are
marketing stem cell interventions, we
conclude that more suitable regulations
are needed, both federally and interna-
tionally, to monitor effectively the clinical
translation of stem cells. While it is impor-
tant that regulations do not needlessly
stifle legitimate medical research and
innovation, priority should always be
given to ensuring patient safety and
protecting vulnerable populations. At the
end of the day, the main concern should
always be the safety and welfare of
patients, as attested in all the medical co-
des of ethics that are promulgated
throughout the world. Enterprises seeking
to profit from the vulnerability of patients
through the marketing of unproven treat-
ments must not prevail.
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